Overview

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with DCM and stable heart failure.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
MyoKardia, Inc.